GHRH | The Pancreatic Tumor That Revealed a Brain Hormone A patient develops acromegaly. Over time, the hands enlarge and the features of the face change. The pituitary is releasing too much growth hormone. But the signal driving it begins in a tumor in the pancreas. That rare case gave researchers a way to find a signal they had long suspected was in the brain. There was so little of it in the hypothalamus that it was hard to isolate. The tumors gave them another source. In November 1982, two teams reported their findings. Roger Guillemin’s group published in Science. Jean Rivier and colleagues published in Nature. Both had isolated a peptide from a human pancreatic tumor that could trigger growth hormone release. In 1983, researchers reported two matching forms in the human hypothalamus. The signal had a name: growth hormone–releasing hormone. GHRH. Here’s how it works. The hypothalamus sends GHRH through small blood vessels to the pituitary. That signal stimulates growth hormone release. Somatostatin also reaches the pituitary, where it restrains that release. Together, these signals help shape the pulses of growth hormone in the blood. Somatostatin led us from the brain to the pancreas. GHRH took us back. The same signal uncovered in a pancreatic tumor helps explain the pathway behind our films on tesamorelin and CJC-1295. Peptides in 2. World Peptide Foundation. Every experience matters.